Box Behnken Design Software Free Download

 

Description

Box Behnken Design software, free download Free

The present paper describes fundamentals, advantages and limitations of the Box-Behnken design (BBD) for the optimization of analytical methods. It establishes also a comparison between this design and composite central, three-level full factorial and Doehlert designs. A detailed study on factors an. In statistics, Box–Behnken designs are experimental designs for response surface methodology, devised by George E. Box and Donald Behnken in 1960, to achieve the following goals:. Each factor, or independent variable, is placed at one of three equally spaced values, usually coded as −1, 0, +1. (At least three levels are needed for the following goal.).

The effective design and analysis of experiments in biology are critical to success, yet graduate students in biological and medical sciences typically receive very little formal training in these steps. With feedback from readers of the first edition, colleagues, and students taking the very popular experimental design courses taught by the author, this second edition of Experimental Design for Biologists retains the engaging writing style while organizing the book around the four elements of experimental design: the framework, the system, the experiment, and the model. The approach has been tested in the classroom, where the author has taught numerous graduate students, MD/PhD students, and postdoctoral fellows. The goal of every scientist is to discover something new and with the aid of Experimental Design for Biologists, this task is made a little easier.

This handbook explains how to establish the framework for an experimental project, how to set up all of the components of an experimental system, design experiments within that system, determine and use the correct set of controls, and formulate models to test the veracity and resiliency of the data. This thoroughly updated edition of Experimental Design for Biologists is an essential source of theory and practical guidance for designing a research plan.

Box Behnken Design software, free download Windows

Behnken

Box Behnken Design software, free download Pc

The oral route is the most prevalent route of drug administration among various routes. Dapagliflozin is an oral hypoglycemic drug used for lowering the blood glucose level. The objective of this work is to developed and optimized dapagliflozin loaded nanostructured lipid carriers (DG-NLCs) for the improvement of oral delivery. DG-NLCs were prepared by a high-pressure homogenization method (hot) and optimized by Box-Behnken design software using lipid, surfactant, and homogenization cycle as an independent variable. DG-NLCs were evaluated for particle size (Y1), entrapment efficiency (Y2), drug release (Y3). The DG-NLCs were further evaluated for morphology, thermal and X-ray diffraction analysis, ex-vivo intestinal permeation, and stability study. Particle size (nm), entrapment efficiency (%) and drug release (%) of all seventeen formulations were found in the range of 113.71-356.22 nm, 60.43-96.54% and 63.44-83.62% respectively. Morphology of optimized formulation exhibited spherical in shape confirmed by transmission electron microscopy. Thermal and X-ray diffraction analysis of NLCs showed the drug was solubilized and lost the crystallinity. DG-NLCs-opt exhibited dual release pattern initial fast and later sustained-release (90.01±2.01% in 24 h) whereas DG-dispersion showed 31.54±1.87% release in 24 h. Korsmeyer-Peppas model was found to be the best fit model (R2=0.999). The DG-NLCs-opt exhibited significant-high (p < 0.05, 1.293 µg/cm2/h) flux than DG-dispersion (0.2683 µg/cm2/h). Apparent permeation coefficient of DG-NLCs-opt was found to be significantly higher (p < 0.05, 4.14×10-5 cm/min) than DG-dispersion (8.61×10-6 cm/min). The formulation showed no significant changes (p < 0.05) on six months of storage study at 25±2°C/60±5%RH. The finding concluded that quality by design (QbD) based lipid nanocarrier for oral delivery could be a promising approach of dapagliflozin for the management of diabetes.